Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Aspirin use improves the biochemical control of prostate cancer in Chinese men.

Hao Q, Gong H, Zong H, Huang S, Wang T, Zhou Y, Zhang Y, Zhang Y.

J BUON. 2018 Nov-Dec;23(6):1803-1808.

PMID:
30610806
2.

Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.

Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn CG, Choe KS, Kim DW.

Cancer Biol Ther. 2014 Jun 1;15(6):699-706. doi: 10.4161/cbt.28554. Epub 2014 Mar 21.

3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
4.

Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.

Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21. doi: 10.1016/j.ijrobp.2009.06.052. Epub 2010 Jan 13.

PMID:
20044216
5.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
6.

Impact of race on biochemical disease recurrence after prostate brachytherapy.

Yamoah K, Stone N, Stock R.

Cancer. 2011 Dec 15;117(24):5589-600. doi: 10.1002/cncr.26183. Epub 2011 Jun 20.

7.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

8.

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8.

PMID:
21985944
9.

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14.

PMID:
19289266
10.

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2003 Feb;169(2):517-23.

PMID:
12544300
11.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
12.
13.
14.

Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy.

Miyake H, Muramaki M, Furukawa J, Tanaka H, Inoue TA, Fujisawa M.

Urol Oncol. 2013 Nov;31(8):1511-6. doi: 10.1016/j.urolonc.2012.05.001. Epub 2012 May 31.

PMID:
22658882
15.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
16.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
17.

A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.

Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA.

Cancer. 2000 Jan 15;88(2):425-32.

PMID:
10640977
18.
19.

Changing nature of high risk patients undergoing radical prostatectomy.

Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ; SEARCH Database Study Group.

J Urol. 2007 Jan;177(1):113-7.

PMID:
17162017
20.

African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Kattan M, Dicker AP, Rebbeck TR.

Urol Oncol. 2015 Feb;33(2):70.e15-22. doi: 10.1016/j.urolonc.2014.07.005. Epub 2014 Oct 7.

Supplemental Content

Support Center